Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antifungal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    113 result(s) found for: Antifungal. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-003571-56 Sponsor Protocol Number: APX001-201 Start Date*: 2018-12-17
    Sponsor Name:Amplyx Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ...
    Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004554-32 Sponsor Protocol Number: PC_ASP_006 Start Date*: 2022-07-09
    Sponsor Name:Pulmocide Ltd
    Full Title: A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonar...
    Medical condition: Refractory invasive pulmonary aspergillosis (IPA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001146-13 Sponsor Protocol Number: A 001 Start Date*: 2006-05-18
    Sponsor Name:University Hospital of Heidelberg
    Full Title: "Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit"
    Medical condition: hospitalised patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002644-23 Sponsor Protocol Number: MB_PDT_1 Start Date*: 2020-07-23
    Sponsor Name:Dept. of Dermatology, Zealand University Hospital, Roskilde
    Full Title: Photodynamic therapy of antifungal resistant dermatophytes
    Medical condition: Competent patients over 18 years old with mycological verified antifungal resistant dermatophytosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043870 Tinea infections HLT
    20.0 10021881 - Infections and infestations 10043868 Tinea cruris PT
    20.0 10021881 - Infections and infestations 10060889 Tinea infection PT
    21.1 10021881 - Infections and infestations 10043873 Tinea pedis PT
    20.0 10021881 - Infections and infestations 10049591 Tinea imbricata PT
    20.0 10021881 - Infections and infestations 10067197 Tinea manuum PT
    20.0 10021881 - Infections and infestations 10043872 Tinea NOS LLT
    20.1 10021881 - Infections and infestations 10043869 Tinea infection NOS LLT
    20.0 10021881 - Infections and infestations 10043867 Tinea corporis LLT
    20.0 10021881 - Infections and infestations 10043864 Tinea LLT
    20.0 10021881 - Infections and infestations 10053041 Tinea trichophytina cruris LLT
    20.0 10021881 - Infections and infestations 10073383 Tinea of hand LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004495-21 Sponsor Protocol Number: GS-MC-131-0165 Start Date*: 2006-09-07
    Sponsor Name:Gilead Sciences GmbH
    Full Title: Pilot study on safety of four weekly administrations of 7 mg/kg of liposomal amphotericin B (AmBisome®) in antifungal primary prophylaxis treatment of elderly patients with acute lymphoblastic leuk...
    Medical condition: Antifungal prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049085 Antifungal prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003172-39 Sponsor Protocol Number: Mica1/2012 Start Date*: 2013-05-23
    Sponsor Name:Medizinische Universität Innsbruck, Abteilung für Hygiene und Medizinische Mikrobiologie
    Full Title: Micafungin-Deescaltion study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients
    Medical condition: All patients who are suspicious of suffering from invasive fungal infections are included.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014527-23 Sponsor Protocol Number: MG-ECALTA1 Start Date*: 2009-10-13
    Sponsor Name:KH der Elisabethinen Linz GmbH, I. Interne Abteilung
    Full Title: Anidulafungin in patients with hematologic malignancies - An open-label, prospective study to evaluate the safety profile at prophylactic and therapeutic dosages
    Medical condition: hematologic malignancies with risk for or active invasive fungal infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001433-74 Sponsor Protocol Number: LOCAL/2017/CR-01 Start Date*: 2017-06-29
    Sponsor Name:CHU de NIMES
    Full Title: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort
    Medical condition: The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000103-16 Sponsor Protocol Number: RC13_0008 Start Date*: 2013-06-21
    Sponsor Name:CHU de Nantes
    Full Title: Antifungal prophylaxis with Micafungin after cord blood allogeneic stem cell transplantation.
    Medical condition: Adult patients receiving allo-Stem Cell Transplantation using Cord Blood as source of stem cells
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10010980 Cord blood transplant therapy PT
    18.0 10042613 - Surgical and medical procedures 10049085 Antifungal prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000627-40 Sponsor Protocol Number: IA-DUET Start Date*: 2020-12-28
    Sponsor Name:Erasmus MC
    Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020814-27 Sponsor Protocol Number: 65091-06093 Start Date*: 2012-05-10
    Sponsor Name:EORTC
    Full Title: Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label pha...
    Medical condition: Invasive fungal infection in patients with hematological malignancies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10017544 Fungemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000904-14 Sponsor Protocol Number: MICA_HDF Start Date*: 2012-07-19
    Sponsor Name:Medizinische Universität Wien
    Full Title: PHARMACOKINETICS OF MICAFUNGIN DURING CONTINUOUS VENOVENOUS HEMOFILTRATION
    Medical condition: Suspected or proven candida infection requiring parenteral antifungal therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001386-33 Sponsor Protocol Number: APX001-202 Start Date*: 2019-08-20
    Sponsor Name:Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.
    Full Title: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients with Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
    Medical condition: Treatment of patients with invasive mold infections (IMIs) caused by Aspergillus species (spp.) or rare molds
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10062642 Invasive mycosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001585-15 Sponsor Protocol Number: 2018-01671 Start Date*: 2020-01-30
    Sponsor Name:Centre Hospitalier Universitaire Vaudois
    Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia
    Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002440-96 Sponsor Protocol Number: 123516 Start Date*: 2004-11-17
    Sponsor Name:South Manchester University Hospitals NHS Trust [...]
    1. South Manchester University Hospitals NHS Trust
    2. University of Manchester
    Full Title: A randomised placebo controlled trial of itraconazole in the treatment of fungal-sensitised patients with severe asthma and without ABPA.
    Medical condition: Asthma and have evidence of fungal sensitisation but not ABPA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005928-17 Sponsor Protocol Number: FTB-11-ITRA01 Start Date*: 2012-04-26
    Sponsor Name:Katholieke Universiteit Leuven - Pharmacotechnology and Biopharmacy
    Full Title: Gastrointestinal behavior of itraconazole in healthy volunteers
    Medical condition: healthy volunteers (administration of antifungal drug)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000381-29 Sponsor Protocol Number: SCY-078-301 Start Date*: 2017-07-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI)
    Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-008382-35 Sponsor Protocol Number: AIFA - FARM07YPBW Start Date*: 2010-04-08
    Sponsor Name:Azienda Ospedaliera di Perugia
    Full Title: Open , multicenter, randomized trial comparing two therapeutic approaches for the treatment of invasive fungal infections in neutropenic onco-hematologic patients.Empiric vs. ``presumptive`` (pree...
    Medical condition: opportunistic fungal infections in neutropenic onco-hematologic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017528 Fungal infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004988-27 Sponsor Protocol Number: FG-463-21-20 Start Date*: 2006-07-27
    Sponsor Name:Astellas Pharma BV
    Full Title: A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THE...
    Medical condition: Patients with haematopoietic stem cell transplantation (HSCT), acute leukaemia, myelodysplastic syndrome (MDS) and with proven (probable only in case of pulmonary aspergillosis) invasive aspergillo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001566-26 Sponsor Protocol Number: BDG-ETHIC Start Date*: 2017-01-11
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: A B-D-GLUCAN DRIVEN ANTIFUNGAL STEWARDSHIP APPROACH TO MANAGE EMPIRICAL THERAPY IN PATIENTS AT VERY HIGH RISK FOR INVASIVE CANDIDIASIS: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: invasive candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 17:52:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA